These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2849127)

  • 1. In vitro metabolism of the phosphorothioate radioprotectors WR-2721 and WR-3689.
    Livesey JC; Rasey JS; Vertrees S; Freeman LM; Magee S; Nelson NJ; Chin L; Grunbaum Z; Krohn KA
    Pharmacol Ther; 1988; 39(1-3):215-7. PubMed ID: 2849127
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.
    Rasey JS; Krohn KA; Magee S; Nelson N; Chin L
    Radiat Res; 1986 Nov; 108(2):167-75. PubMed ID: 3024202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pharmacokinetics of WR-2721.
    Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
    Utley JF; Marlowe C; Waddell WJ
    Radiat Res; 1976 Nov; 68(2):284-91. PubMed ID: 185642
    [No Abstract]   [Full Text] [Related]  

  • 5. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
    Calabro-Jones PM; Fahey RC; Smoluk GD; Ward JF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jan; 47(1):23-7. PubMed ID: 2982751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in normal tissue responsiveness to WR-2721.
    Yuhas JM; Afzal SM; Afzal V
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1537-9. PubMed ID: 6090357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of amifostine.
    Shaw LM; Bonner H; Lieberman R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dephosphorylation of WR-2721 with mouse tissue homogenates.
    Mori T; Nikaido O; Sugahara T
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1529-31. PubMed ID: 6090356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
    Utley JF; Seaver N; Newton GL; Fahey RC
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.
    Calabro-Jones PM; Aguilera JA; Ward JF; Smoluk GD; Fahey RC
    Cancer Res; 1988 Jul; 48(13):3634-40. PubMed ID: 2837319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors.
    Fleckenstein L; Swynnerton NF; Ludden TM; Mangold DJ
    Pharmacol Ther; 1988; 39(1-3):203-12. PubMed ID: 2849124
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
    Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the radioprotective effects of YM-08310 (= WR-2721) Part 1: Radioprotective effects of YM-08310 on normal and malignant tissues in mice].
    Tanaka Y; Akagi K; Hasegawa T; Nakazawa M; Harima K; Murata T; Sawada S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 May; 43(5):700-9. PubMed ID: 6312407
    [No Abstract]   [Full Text] [Related]  

  • 15. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913).
    Rasey JS; Grunbaum Z; Krohn KA; Menard TW; Spence AM
    Radiat Res; 1985 Apr; 102(1):130-7. PubMed ID: 2984715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of WR-2721 toxicity and radioprotection by an inhibitor of alkaline phosphatase.
    Brown DQ; Shaw LM; Pittock JW; Mann DJ; Hardiman J; Pogach R; Gold J
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1491-3. PubMed ID: 3019966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity and biodistribution of the radioprotectors, WR2721, WR77913, and WR3689, in the CNS following intraventricular or intracisternal administration.
    Spence AM; Edmondson SW; Krohn KA; Grunbaum Z; Rasey JS; Steele JE
    Int J Radiat Oncol Biol Phys; 1986 Sep; 12(9):1653-60. PubMed ID: 3019970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins.
    Livesey JC; Grunbaum Z; Krohn KA
    Biochem Pharmacol; 1990 Jun; 39(11):1807-12. PubMed ID: 2160821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats.
    Lam TT; Liu D; Brody MA; Chu R; Tso MO
    Exp Eye Res; 1991 Jun; 52(6):661-7. PubMed ID: 1649765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689).
    Rasey JS; Krohn KA; Grunbaum Z; Spence AM; Menard TW; Wade RA
    Radiat Res; 1986 Jun; 106(3):366-79. PubMed ID: 3012625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.